These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
733 related articles for article (PubMed ID: 31605325)
21. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
22. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090 [TBL] [Abstract][Full Text] [Related]
23. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073 [TBL] [Abstract][Full Text] [Related]
24. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
25. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer. Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245 [TBL] [Abstract][Full Text] [Related]
26. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019 [TBL] [Abstract][Full Text] [Related]
27. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965 [TBL] [Abstract][Full Text] [Related]
28. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
29. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745 [TBL] [Abstract][Full Text] [Related]
30. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398 [TBL] [Abstract][Full Text] [Related]
32. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570 [TBL] [Abstract][Full Text] [Related]
33. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499 [TBL] [Abstract][Full Text] [Related]
34. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Zhang X; Zhao P; Wang C; Xin B Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032 [TBL] [Abstract][Full Text] [Related]
35. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555 [TBL] [Abstract][Full Text] [Related]